Biotech Values

[bellweather1]

Ariad Investors have to hope that if EU doctors are, by and large, more sophisticated, that will translate into stricter adherence to newly advanced switch criteria,

and that this factor will sufficiently offset greater cost consciousness in the EU.

I'm hopeful, because this kind of approach would play to Iclusig's biggest advantage:efficacy.